BioWorld Asia

Jan. 30, 2002

UroGene, Pierre Fabre Enter 3-Year Cancer Collaboration

PARIS UroGene SA entered into a three-year research collaboration with Pierre Fabre M dicament to discover and develop new active compounds to treat prostate cancer against a validated biological target identified by UroGene. (BioWorld International) Read More

Symphogen Raises US$15M To Develop Polyclonal Antibodies

Peptide Study Yields Insights Into Autoimmune Disease Mechanisms

Synt:em, Baxter Collaborate On Peptide Mimetics Of MAbs

UK Creating Centers To Help Capitalize On Genetics Progress

Galapagos, Exelixis Collaborate To Analyze Functions Of Genes

Biogen Paying Schering $20M Or More Over MS Drug Patents

BIA Calls For More Support To Deal With Animal Rights Activists

Dutch Biotech Association Seeks Clearer Signals From Politicians

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...